Literature DB >> 17568787

Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.

William G Goodman1, L D Quarles.   

Abstract

The identification of the calcium-sensing receptor (CaSR) and the clarification of its role as the major regulator of parathyroid gland function have important implications for understanding the pathogenesis and evolution of secondary hyperthyroidism in chronic kidney disease (CKD). Signaling through the CaSR has direct effects on three discrete components of parathyroid gland function, which include parathyroid hormone (PTH) secretion, PTH synthesis, and parathyroid gland hyperplasia. Disturbances in calcium and vitamin D metabolism that arise owing to CKD diminish the level of activation of the CaSR, leading to increases in PTH secretion, PTH synthesis, and parathyroid gland hyperplasia. Each represents a physiological adaptive response by the parathyroid glands to maintain plasma calcium homeostasis. Studies of genetically modified mice indicate that signal transduction via the CaSR is a key determinant of parathyroid cell proliferation and parathyroid gland hyperplasia. Because enlargement of the parathyroid glands has important implications for disease progression and disease severity, it is possible that clinical management strategies that maintain adequate calcium-dependent signaling through the CaSR will ultimately prove useful in diminishing parathyroid gland hyperplasia and in modifying disease progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568787     DOI: 10.1038/sj.ki.5002287

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  52 in total

Review 1.  Bone Disease in CKD in Children.

Authors:  Fernando Santos; Lucas Díaz-Anadón; Flor A Ordóñez; Dieter Haffner
Journal:  Calcif Tissue Int       Date:  2021-01-16       Impact factor: 4.333

2.  A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.

Authors:  David E Leaf; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2012-08-30       Impact factor: 8.860

3.  Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Authors:  Pieter Evenepoel; Björn Meijers; Liesbeth Viaene; Bert Bammens; Kathleen Claes; Dirk Kuypers; Dirk Vanderschueren; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

4.  Associations of parathyroid hormone levels and mineral parameters with heart rate variability in patients with end-stage renal disease.

Authors:  Lei Zhang; Shaoyan Yang; Jianling Chen; Jinling Ma; Yueqin Ren
Journal:  Int Urol Nephrol       Date:  2017-02-27       Impact factor: 2.370

Review 5.  Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review.

Authors:  Jonathan Sivakumar
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-12-25

6.  Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis.

Authors:  Jessica E Miller; Miklos Z Molnar; Csaba P Kovesdy; Joshua J Zaritsky; Elani Streja; Isidro Salusky; Onyebuchi A Arah; Kamyar Kalantar-Zadeh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-09-20       Impact factor: 2.890

7.  Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.

Authors:  Yudan Wei; Jing Lin; Fan Yang; Xiujiang Li; Yue Hou; Ronghua Lu; Xiaonv Shi; Zhi Liu; Yujun Du
Journal:  Exp Ther Med       Date:  2016-06-08       Impact factor: 2.447

Review 8.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney.

Authors:  Daniela Riccardi; Edward M Brown
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18

9.  Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.

Authors:  Christian S Shinaberger; Joel D Kopple; Csaba P Kovesdy; Charles J McAllister; David van Wyck; Sander Greenland; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

10.  Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.

Authors:  Vasily Belozeroff; William G Goodman; Lulu Ren; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.